Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance

The Splicing Factor RBM4 Controls Apoptosis, Proliferation, and Migration to Suppress Tumor Progression

(2014) Yang Wang et al.   CANCER CELL

Comprehensive Overview of the Structure and Regulation of the Glucocorticoid Receptor

(2014) Sofie Vandevyver et al.   ENDOCRINE REVIEWS

Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma

(2014) Hideki Makinoshima et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling

(2014) Meike de Wit et al.   Journal of Proteomics

Emerging Functions of SRSF1, Splicing Factor and Oncoprotein, in RNA Metabolism and Cancer

(2014) S. Das et al.   MOLECULAR CANCER RESEARCH

Context-dependent control of alternative splicing by RNA-binding proteins

(2014) Xiang-Dong Fu et al.   NATURE REVIEWS GENETICS

Sudemycin E influences alternative splicing and changes chromatin modifications

(2014) Paolo Convertini et al.   NUCLEIC ACIDS RESEARCH

Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells

(2014) Yang Gao et al.   Scientific Reports

Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic

(2014) Pedro M. D. Moreno et al.   Frontiers in Chemistry

Chemical Perturbation of Mcl-1 Pre-mRNA Splicing to Induce Apoptosis in Cancer Cells

(2013) Yang Gao et al.   ACS Chemical Biology

Eteplirsen for the treatment of Duchenne muscular dystrophy

(2013) Jerry R. Mendell et al.   ANNALS OF NEUROLOGY

The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context

(2013) Tieneke B.M. Schaaij-Visser et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Conjugation with Receptor-Targeted Histidine-Rich Peptides Enhances the Pharmacological Effectiveness of Antisense Oligonucleotides

(2013) Osamu Nakagawa et al.   BIOCONJUGATE CHEMISTRY

Clinical and biological implications of driver mutations in myelodysplastic syndromes

(2013) E. Papaemmanuil et al.   BLOOD

Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo

(2013) T O Nielsen et al.   BRITISH JOURNAL OF CANCER

Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy

(2013) F. Vegran et al.   CANCER RESEARCH

mRNA Splicing Variants: Exploiting Modularity to Outwit Cancer Therapy

(2013) S. M. Dehm   CANCER RESEARCH

A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets

(2013) Sophia Adamia et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

(2013) F. A. L. M. Eskens et al.   CLINICAL CANCER RESEARCH

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

(2013) D. S. Hong et al.   INVESTIGATIONAL NEW DRUGS

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

(2013) Raphaël Itzykson et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomics-Guided Discovery of Thailanstatins A, B, and C As Pre-mRNA Splicing Inhibitors and Antiproliferative Agents from Burkholderia thailandensis MSMB43

(2013) Xiangyang Liu et al.   JOURNAL OF NATURAL PRODUCTS

Oncogenic H-Ras Reprograms Madin-Darby Canine Kidney (MDCK) Cell-derived Exosomal Proteins Following Epithelial-Mesenchymal Transition

(2013) Bow J. Tauro et al.   MOLECULAR & CELLULAR PROTEOMICS

BIRC5(survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group

(2013) Andrew S. Moore et al.   PEDIATRIC BLOOD & CANCER

Spliceosome mutations involvingSRSF2,SF3B1, andU2AF35in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance

(2012) Mrinal M. Patnaik et al.   AMERICAN JOURNAL OF HEMATOLOGY

Regulation of chemoresistance via alternative messenger RNA splicing

(2012) Scott T. Eblen   BIOCHEMICAL PHARMACOLOGY

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

(2012) F. Damm et al.   BLOOD

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

(2012) F. Thol et al.   BLOOD

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)

(2012) M. Meggendorfer et al.   BLOOD

Splicing in oncogenesis and tumor suppression

(2012) Daisuke Kaida et al.   CANCER SCIENCE

Splice Modulating Therapies for Human Disease

(2012) Pietro Spitali et al.   CELL

Transcript Dynamics of Proinflammatory Genes Revealed by Sequence Analysis of Subcellular RNA Fractions

(2012) Dev M. Bhatt et al.   CELL

Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co-transcriptional in the human genome but inefficient for lncRNAs

(2012) H. Tilgner et al.   GENOME RESEARCH

Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia

(2012) S. A. Kar et al.   HAEMATOLOGICA

Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders

(2012) V Visconte et al.   LEUKEMIA

Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies

(2012) F Damm et al.   LEUKEMIA

The spliceosome as a target of novel antitumour drugs

(2012) Sophie Bonnal et al.   NATURE REVIEWS DRUG DISCOVERY

The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation

(2012) Olga Anczuków et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Abnormal Expression of the Pre-mRNA Splicing Regulators SRSF1, SRSF2, SRPK1 and SRPK2 in Non Small Cell Lung Carcinoma

(2012) Stephanie Gout et al.   PLoS One

Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing

(2011) Liying Fan et al.   ACS Chemical Biology

Identification of genes associated to 2′,2′-difluorodeoxycytidine resistance in HeLa cells with a lentiviral short-hairpin RNA library

(2011) Yunjian Xu et al.   BIOCHEMICAL PHARMACOLOGY

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

(2011) L. Malcovati et al.   BLOOD

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

(2011) D. Rossi et al.   BLOOD

RNA splicing: disease and therapy

(2011) A. G. L. Douglas et al.   Briefings in Functional Genomics

Amiloride Modulates Alternative Splicing in Leukemic Cells and ResensitizesBcr-AblT315I Mutant Cells to Imatinib

(2011) Wen-Hsin Chang et al.   CANCER RESEARCH

The RNA polymerase II C-terminal domain promotes splicing activation through recruitment of a U2AF65-Prp19 complex

(2011) C. J. David et al.   GENES & DEVELOPMENT

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

(2011) Timothy A Graubert et al.   NATURE GENETICS

Mutations in RNA Splicing Machinery in Human Cancers

(2011) Benjamin Ebert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small Molecule Amiloride Modulates Oncogenic RNA Alternative Splicing to Devitalize Human Cancer Cells

(2011) Jan-Gowth Chang et al.   PLoS One

Antitumorigenic potential of STAT3 alternative splicing modulation

(2011) F. Zammarchi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pause locally, splice globally

(2011) Fernando Carrillo Oesterreich et al.   TRENDS IN CELL BIOLOGY

Understanding splicing regulation through RNA splicing maps

(2011) Joshua T. Witten et al.   TRENDS IN GENETICS

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged

(2010) C. J. David et al.   GENES & DEVELOPMENT

Cellular Processing of the Glucocorticoid Receptor Gene and Protein: New Mechanisms for Generating Tissue-specific Actions of Glucocorticoids

(2010) Robert H. Oakley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Heterogeneous Nuclear Ribonucleoprotein H1/H2-dependent Unsplicing of Thymidine Phosphorylase Results in Anticancer Drug Resistance

(2010) Michal Stark et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Global Analysis of Nascent RNA Reveals Transcriptional Pausing in Terminal Exons

(2010) Fernando Carrillo Oesterreich et al.   MOLECULAR CELL

Expansion of the eukaryotic proteome by alternative splicing

(2010) Timothy W. Nilsen et al.   NATURE

Anti-tumor activity of splice-switching oligonucleotides

(2010) John A. Bauman et al.   NUCLEIC ACIDS RESEARCH

Spliceosome Structure and Function

(2010) C. L. Will et al.   Cold Spring Harbor Perspectives in Biology

Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia

(2009) M. Stark et al.   BLOOD

The Spliceosome: Design Principles of a Dynamic RNP Machine

(2009) Markus C. Wahl et al.   CELL

Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells

(2009) B. J. Albert et al.   MOLECULAR CANCER THERAPEUTICS

The Isoforms of the p53 Protein

(2009) M. P. Khoury et al.   Cold Spring Harbor Perspectives in Biology

Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells

(2008) J. Cai et al.   CANCER RESEARCH

Alternative Splicing and Tumor Progression

(2008) Claudia Ghigna et al.   CURRENT GENOMICS

The emerging role of splicing factors in cancer

(2008) Ana Rita Grosso et al.   EMBO REPORTS

Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes

(2008) Lulzim Shkreta et al.   MOLECULAR CANCER THERAPEUTICS